325 Capital LLC
Net buyer this quarter
$419M
12
+$48.4M
97.8%
Holdings
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026 | |||||
 ASTH | $74.9M | 17.85% | 2.90% | -12.3% | Q3 2022 |
 MGNI | $64.8M | 15.44% | 2.38% | +70.2% | Q3 2025 |
 APEI | $63.6M | 15.15% | 6.44% | Not reported | Q4 2021 |
 BLBD | $56.2M | 13.39% | 2.25% | +4.6% | Q4 2021 |
 SPIR | $55.2M | 13.16% | Not reported | +58.2% | Q1 2025 |
 MPAA | $30.9M | 7.37% | 10.66% | Not reported | Q4 2021 |
 DBD | $20.6M | 4.91% | 0.71% | Not reported | Q4 2025 |
 AIOT | $20.2M | 4.82% | 3.94% | +37.7% | Q4 2024 |
 LFCR | $15.2M | 3.62% | 7.68% | +33.9% | Q4 2023 |
 BTMD | $8.6M | 2.05% | 7.81% | Not reported | Q1 2023 |
 TACT | $5.91M | 1.41% | 9.80% | Not reported | Q4 2021 |
 MSAI | $3.45M | 0.82% | 30.02% | 0.0% | Q3 2024 |
| Q1 2026 | |||||
| APEI | $67.3M | 24.53% | 6.43% | -22.6% | Q4 2021 |
| ASTH | $45.1M | 16.43% | 3.31% | Not reported | Q3 2022 |
| BLBD | $38.6M | 14.07% | 2.15% | Not reported | Q4 2021 |
| MGNI | $23.8M | 8.68% | 1.40% | Not reported | Q3 2025 |
| SPIR | $23.6M | 8.59% | Not reported | Not reported | Q1 2025 |
| MPAA | $22.3M | 8.13% | 10.67% | Not reported | Q4 2021 |
| DBD | $18.3M | 6.65% | 0.70% | +25.2% | Q4 2025 |
| AIOT | $11.8M | 4.31% | 2.86% | Not reported | Q4 2024 |
| LFCR | $8.04M | 2.93% | 5.77% | Not reported | Q4 2023 |
| BTMD | $6.14M | 2.24% | 7.81% | Not reported | Q1 2023 |
| MSAI | $6.12M | 2.23% | 1316.40% | Not reported | Q3 2024 |
| TACT | $3.33M | 1.21% | 9.85% | Not reported | Q4 2021 |
| Q4 2025 | |||||
| APEI | $57.8M | 20.24% | 8.43% | Not reported | Q4 2021 |
| ASTH | $45.6M | 15.99% | 3.76% | +54.0% | Q3 2022 |
| MGNI | $32.5M | 11.40% | 1.40% | +208.5% | Q3 2025 |
| BLBD | $32M | 11.20% | 2.15% | -12.1% | Q4 2021 |
| MPAA | $24.9M | 8.73% | 10.51% | Not reported | Q4 2021 |
| AIOT | $20.4M | 7.15% | 2.86% | +5.2% | Q4 2024 |
| LFCR | $17.7M | 6.20% | 5.77% | Not reported | Q4 2023 |
| SPIR | $14.1M | 4.93% | Not reported | Not reported | Q1 2025 |
| DBD | $13.1M | 4.60% | 0.55% | New | Q4 2025 |
| BTMD | $11.8M | 4.14% | 7.81% | Not reported | Q1 2023 |
| MSAI | $7.63M | 2.67% | 1319.47% | +182.6% | Q3 2024 |
| TACT | $4.05M | 1.42% | 9.99% | Not reported | Q4 2021 |
 ATRO | $3.8M | 1.33% | 0.22% | -94.9% | Q4 2021 |
| Q3 2025 | |||||
| ATRO | $62.1M | 18.86% | 4.21% | Not reported | Q4 2021 |
| APEI | $60.3M | 18.33% | 8.45% | Not reported | Q4 2021 |
| BLBD | $44.5M | 13.52% | 2.43% | Not reported | Q4 2021 |
| ASTH | $33.8M | 10.29% | 2.13% | +34.6% | Q3 2022 |
| MPAA | $33.4M | 10.15% | 10.33% | Not reported | Q4 2021 |
| SPIR | $20.6M | 6.26% | Not reported | Not reported | Q1 2025 |
| AIOT | $19.1M | 5.81% | 2.73% | Not reported | Q4 2024 |
| LFCR | $15.9M | 4.84% | 5.77% | Not reported | Q4 2023 |
| MGNI | $14.2M | 4.30% | 0.45% | New | Q3 2025 |
| BTMD | $13.6M | 4.15% | 7.81% | Not reported | Q1 2023 |
| MSAI | $6.05M | 1.84% | 27.01% | Not reported | Q3 2024 |
| TACT | $5.48M | 1.67% | 10.01% | Not reported | Q4 2021 |